VarmX B.V. is manufacturing therapeutic proteins to instantaneously restore blood clotting in bleeding patients.
VarmX has raised $15.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2025.
VarmX's investors include EQT Life Sciences, Ysios Capital, Inkef, European Innovation Council, BioGeneration Ventures.
VarmX is headquartered in Leiden, The Netherlands.
VarmX B.V. is manufacturing therapeutic proteins to instantaneously restore blood clotting in bleeding patients.
VarmX is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"VarmX — Funding & Investors." VCBacked, February 25, 2025, https://www.vcbacked.co/company/varmx. Accessed July 19, 2026.
VCBacked. (2025). VarmX — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/varmx
{{cite web |title=VarmX — Funding & Investors |url=https://www.vcbacked.co/company/varmx |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated